An official website of the United States government
Home
Name
Vismodegib
Alternate Names
Erivedge
GDC-0449
Abbreviations
None
Category
Chemotherapy
Subcategory
Hedgehog signaling pathway targeting agent
cyclopamine-competitive antagonist othe the smoothened receptor (SMO)
NSC Number
747691
Primary Site
Histology
None
Remarks
Received FDA approval January 30, 2012 for the treatment of basal cell carcinoma (BCC). Is currently in clinical trials for advanced stomach cancer, pancreatic cancer, small-cell lung cancer, colorectal cancer, medulloblastoma and chondrosarcoma.
Coding
This drug should be coded
